Which has higher valuation & earnings, IKT or PYPD?

Inhibikase Therapeutics is trading at a lower price-to-earnings ratio than PolyPid, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Inhibikase Therapeutics N/A N/A -$48.26M -$0.43 N/A PolyPid N/A N/A -$34.17M -$1.48 N/A

Is IKT or PYPD more profitable?

Inhibikase Therapeutics' return on equity of -42.80% beat PolyPid's return on equity. Company Net Margins Return on Equity Return on Assets Inhibikase Therapeutics N/A -42.80% -40.58% PolyPid N/A -311.08% -150.83%

Does the media favor PYPD or VNDA?

In the previous week, PolyPid and PolyPid both had 2 articles in the media. Vanda Pharmaceuticals' average media sentiment score of 0.84 beat PolyPid's score of 0.61 indicating that Vanda Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PolyPid 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vanda Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, PYPD or AMRN?

PolyPid has higher earnings, but lower revenue than Amarin. Amarin is trading at a lower price-to-earnings ratio than PolyPid, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PolyPid N/A N/A -$34.17M -$1.48 N/A Amarin $186.23M 1.57 -$38.80M -$0.99 N/A

Is PYPD or AMRN more profitable?

PolyPid has a net margin of 0.00% compared to Amarin's net margin of -14.56%. Amarin's return on equity of -0.20% beat PolyPid's return on equity. Company Net Margins Return on Equity Return on Assets PolyPid N/A -311.08% -150.83% Amarin -14.56% -0.20% -0.14%

Does the media prefer PYPD or AMRN?

In the previous week, Amarin had 5 more articles in the media than PolyPid. MarketBeat recorded 7 mentions for Amarin and 2 mentions for PolyPid. PolyPid's average media sentiment score of 0.61 beat Amarin's score of -0.29 indicating that PolyPid is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PolyPid 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amarin 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation & earnings, PYPD or NMRA?

PolyPid is trading at a lower price-to-earnings ratio than Neumora Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PolyPid N/A N/A -$34.17M -$1.48 N/A Neumora Therapeutics N/A N/A -$236.93M -$1.23 N/A

Is PYPD or NMRA more profitable?

Neumora Therapeutics' return on equity of -242.28% beat PolyPid's return on equity. Company Net Margins Return on Equity Return on Assets PolyPid N/A -311.08% -150.83% Neumora Therapeutics N/A -242.28% -131.32%

Does the media refer more to PYPD or NMRA?

In the previous week, Neumora Therapeutics had 28 more articles in the media than PolyPid. MarketBeat recorded 30 mentions for Neumora Therapeutics and 2 mentions for PolyPid. PolyPid's average media sentiment score of 0.61 beat Neumora Therapeutics' score of 0.21 indicating that PolyPid is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PolyPid 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Neumora Therapeutics 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings & valuation, PYPD or TTRX?

Turn Therapeutics is trading at a lower price-to-earnings ratio than PolyPid, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PolyPid N/A N/A -$34.17M -$1.48 N/A Turn Therapeutics N/A N/A -$3.19M -$0.29 N/A

Is PYPD or TTRX more profitable?

Turn Therapeutics' return on equity of -230.84% beat PolyPid's return on equity. Company Net Margins Return on Equity Return on Assets PolyPid N/A -311.08% -150.83% Turn Therapeutics N/A -230.84% -53.19%

Does the media refer more to PYPD or TTRX?

In the previous week, PolyPid and PolyPid both had 2 articles in the media. PolyPid's average media sentiment score of 0.61 beat Turn Therapeutics' score of 0.34 indicating that PolyPid is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PolyPid 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Turn Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

PolyPid (PYPD) Competitors

$4.99 -0.11 (-2.16%)

Closing price 04:00 PM Eastern

Extended Trading

$5.00 +0.01 (+0.20%)

As of 04:10 PM Eastern

Compare

PYPD vs. IKT, VNDA, AMRN, NMRA, and TTRX

Should you buy PolyPid stock or one of its competitors? PolyPid's main competitors and comparable companies include Inhibikase Therapeutics (IKT), Vanda Pharmaceuticals (VNDA), Amarin (AMRN), Neumora Therapeutics (NMRA), and Turn Therapeutics (TTRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does PolyPid compare to Inhibikase Therapeutics?

Inhibikase Therapeutics (NASDAQ:IKT) and PolyPid (NASDAQ:PYPD) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, dividends, risk and media sentiment.

Inhibikase Therapeutics is trading at a lower price-to-earnings ratio than PolyPid, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibikase Therapeutics	N/A	N/A	-$48.26M	-$0.43	N/A
PolyPid	N/A	N/A	-$34.17M	-$1.48	N/A

3.8% of Inhibikase Therapeutics shares are held by institutional investors. Comparatively, 26.5% of PolyPid shares are held by institutional investors. 7.1% of Inhibikase Therapeutics shares are held by company insiders. Comparatively, 24.7% of PolyPid shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Inhibikase Therapeutics' return on equity of -42.80% beat PolyPid's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inhibikase Therapeutics	N/A	-42.80%	-40.58%
PolyPid	N/A	-311.08%	-150.83%

In the previous week, PolyPid had 2 more articles in the media than Inhibikase Therapeutics. MarketBeat recorded 2 mentions for PolyPid and 0 mentions for Inhibikase Therapeutics. PolyPid's average media sentiment score of 0.61 beat Inhibikase Therapeutics' score of 0.00 indicating that PolyPid is being referred to more favorably in the news media.

Company	Overall Sentiment
Inhibikase Therapeutics	Neutral
PolyPid	Positive

Inhibikase Therapeutics has a beta of 0.95, meaning that its stock price is 5% less volatile than the broader market. Comparatively, PolyPid has a beta of 1.41, meaning that its stock price is 41% more volatile than the broader market.

Inhibikase Therapeutics currently has a consensus price target of $5.40, indicating a potential upside of 116.00%. PolyPid has a consensus price target of $11.33, indicating a potential upside of 127.12%. Given PolyPid's higher possible upside, analysts clearly believe PolyPid is more favorable than Inhibikase Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibikase Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.00
PolyPid	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

PolyPid beats Inhibikase Therapeutics on 8 of the 14 factors compared between the two stocks.

How does PolyPid compare to Vanda Pharmaceuticals?

PolyPid (NASDAQ:PYPD) and Vanda Pharmaceuticals (NASDAQ:VNDA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, risk, earnings, profitability, analyst recommendations and valuation.

PolyPid presently has a consensus price target of $11.33, suggesting a potential upside of 127.12%. Vanda Pharmaceuticals has a consensus price target of $13.70, suggesting a potential upside of 157.04%. Given Vanda Pharmaceuticals' higher probable upside, analysts clearly believe Vanda Pharmaceuticals is more favorable than PolyPid.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PolyPid	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Vanda Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

26.5% of PolyPid shares are owned by institutional investors. Comparatively, 88.1% of Vanda Pharmaceuticals shares are owned by institutional investors. 24.7% of PolyPid shares are owned by company insiders. Comparatively, 10.7% of Vanda Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

PolyPid has a net margin of 0.00% compared to Vanda Pharmaceuticals' net margin of -127.41%. Vanda Pharmaceuticals' return on equity of -49.81% beat PolyPid's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PolyPid	N/A	-311.08%	-150.83%
Vanda Pharmaceuticals	-127.41%	-49.81%	-33.29%

In the previous week, PolyPid and PolyPid both had 2 articles in the media. Vanda Pharmaceuticals' average media sentiment score of 0.84 beat PolyPid's score of 0.61 indicating that Vanda Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PolyPid	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vanda Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

PolyPid has higher earnings, but lower revenue than Vanda Pharmaceuticals. PolyPid is trading at a lower price-to-earnings ratio than Vanda Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PolyPid	N/A	N/A	-$34.17M	-$1.48	N/A
Vanda Pharmaceuticals	$216.10M	1.49	-$220.47M	-$4.63	N/A

PolyPid has a beta of 1.41, meaning that its share price is 41% more volatile than the broader market. Comparatively, Vanda Pharmaceuticals has a beta of 0.64, meaning that its share price is 36% less volatile than the broader market.

Summary

Vanda Pharmaceuticals beats PolyPid on 8 of the 13 factors compared between the two stocks.

How does PolyPid compare to Amarin?

PolyPid (NASDAQ:PYPD) and Amarin (NASDAQ:AMRN) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, earnings, analyst recommendations, institutional ownership, dividends, risk, valuation and profitability.

PolyPid presently has a consensus target price of $11.33, indicating a potential upside of 127.12%. Amarin has a consensus target price of $13.00, indicating a potential downside of 6.07%. Given PolyPid's stronger consensus rating and higher possible upside, research analysts plainly believe PolyPid is more favorable than Amarin.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PolyPid	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Amarin	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.33

PolyPid has a net margin of 0.00% compared to Amarin's net margin of -14.56%. Amarin's return on equity of -0.20% beat PolyPid's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PolyPid	N/A	-311.08%	-150.83%
Amarin	-14.56%	-0.20%	-0.14%

In the previous week, Amarin had 5 more articles in the media than PolyPid. MarketBeat recorded 7 mentions for Amarin and 2 mentions for PolyPid. PolyPid's average media sentiment score of 0.61 beat Amarin's score of -0.29 indicating that PolyPid is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PolyPid	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Amarin	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

PolyPid has higher earnings, but lower revenue than Amarin. Amarin is trading at a lower price-to-earnings ratio than PolyPid, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PolyPid	N/A	N/A	-$34.17M	-$1.48	N/A
Amarin	$186.23M	1.57	-$38.80M	-$0.99	N/A

26.5% of PolyPid shares are owned by institutional investors. Comparatively, 22.3% of Amarin shares are owned by institutional investors. 24.7% of PolyPid shares are owned by insiders. Comparatively, 4.2% of Amarin shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

PolyPid has a beta of 1.41, suggesting that its stock price is 41% more volatile than the broader market. Comparatively, Amarin has a beta of 0.81, suggesting that its stock price is 19% less volatile than the broader market.

Summary

PolyPid beats Amarin on 10 of the 15 factors compared between the two stocks.

How does PolyPid compare to Neumora Therapeutics?

PolyPid (NASDAQ:PYPD) and Neumora Therapeutics (NASDAQ:NMRA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, risk, dividends, profitability, analyst recommendations, earnings and valuation.

Neumora Therapeutics' return on equity of -242.28% beat PolyPid's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PolyPid	N/A	-311.08%	-150.83%
Neumora Therapeutics	N/A	-242.28%	-131.32%

PolyPid has a beta of 1.41, meaning that its share price is 41% more volatile than the broader market. Comparatively, Neumora Therapeutics has a beta of 2.75, meaning that its share price is 175% more volatile than the broader market.

In the previous week, Neumora Therapeutics had 28 more articles in the media than PolyPid. MarketBeat recorded 30 mentions for Neumora Therapeutics and 2 mentions for PolyPid. PolyPid's average media sentiment score of 0.61 beat Neumora Therapeutics' score of 0.21 indicating that PolyPid is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PolyPid	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Neumora Therapeutics	7 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

26.5% of PolyPid shares are owned by institutional investors. Comparatively, 47.7% of Neumora Therapeutics shares are owned by institutional investors. 24.7% of PolyPid shares are owned by company insiders. Comparatively, 26.9% of Neumora Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

PolyPid is trading at a lower price-to-earnings ratio than Neumora Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PolyPid	N/A	N/A	-$34.17M	-$1.48	N/A
Neumora Therapeutics	N/A	N/A	-$236.93M	-$1.23	N/A

PolyPid presently has a consensus price target of $11.33, suggesting a potential upside of 127.12%. Neumora Therapeutics has a consensus price target of $6.57, suggesting a potential upside of 330.91%. Given Neumora Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Neumora Therapeutics is more favorable than PolyPid.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PolyPid	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Neumora Therapeutics	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.60

Summary

Neumora Therapeutics beats PolyPid on 12 of the 14 factors compared between the two stocks.

How does PolyPid compare to Turn Therapeutics?

PolyPid (NASDAQ:PYPD) and Turn Therapeutics (NASDAQ:TTRX) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, media sentiment, dividends, analyst recommendations, valuation, risk and profitability.

Turn Therapeutics is trading at a lower price-to-earnings ratio than PolyPid, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PolyPid	N/A	N/A	-$34.17M	-$1.48	N/A
Turn Therapeutics	N/A	N/A	-$3.19M	-$0.29	N/A

Turn Therapeutics' return on equity of -230.84% beat PolyPid's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PolyPid	N/A	-311.08%	-150.83%
Turn Therapeutics	N/A	-230.84%	-53.19%

In the previous week, PolyPid and PolyPid both had 2 articles in the media. PolyPid's average media sentiment score of 0.61 beat Turn Therapeutics' score of 0.34 indicating that PolyPid is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PolyPid	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Turn Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

26.5% of PolyPid shares are owned by institutional investors. 24.7% of PolyPid shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

PolyPid currently has a consensus target price of $11.33, suggesting a potential upside of 127.12%. Turn Therapeutics has a consensus target price of $8.00, suggesting a potential downside of 17.36%. Given PolyPid's higher probable upside, analysts plainly believe PolyPid is more favorable than Turn Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PolyPid	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Turn Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Summary

PolyPid beats Turn Therapeutics on 6 of the 11 factors compared between the two stocks.

Get PolyPid News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PYPD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PYPD vs. The Competition

Export

Metric	PolyPid	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$95.22M	$12.42B	$7.29B	$12.71B
Dividend Yield	N/A	2.62%	2.54%	10.79%
P/E Ratio	-3.37	780.42	271.39	24.10
Price / Sales	N/A	789.54	604.58	77.05
Price / Cash	N/A	15.47	29.03	36.90
Price / Book	7.23	10.42	11.18	6.40
Net Income	-$34.17M	$2.79B	$3.46B	$348.28M
7 Day Performance	4.61%	2.25%	1.98%	0.92%
1 Month Performance	27.95%	4.72%	7.32%	5.10%
1 Year Performance	42.57%	7.07%	24.76%	16.16%

PolyPid Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PYPD PolyPid	2.515 of 5 stars	$4.99 -2.2%	$11.33 +127.1%	+45.7%	$95.22M	N/A	N/A	80
IKT Inhibikase Therapeutics	1.4202 of 5 stars	$2.40 +0.4%	$5.40 +125.0%	N/A	$336.28M	$260K	N/A	6
VNDA Vanda Pharmaceuticals	3.1114 of 5 stars	$5.44 +3.4%	$13.70 +151.8%	+11.2%	$318.04M	$215.72M	N/A	290
AMRN Amarin	0.8177 of 5 stars	$14.13 +0.9%	N/A	-11.8%	$297.20M	$213.65M	N/A	360	News Coverage Analyst Forecast
NMRA Neumora Therapeutics	2.9098 of 5 stars	$1.64 +7.9%	$6.57 +300.7%	+0.6%	$296.45M	N/A	N/A	108	Positive News Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PYPD) was last updated on 8/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PolyPid (PYPD) Competitors

PYPD vs. IKT, VNDA, AMRN, NMRA, and TTRX

How does PolyPid compare to Inhibikase Therapeutics?

Summary

How does PolyPid compare to Vanda Pharmaceuticals?

Summary

How does PolyPid compare to Amarin?

Summary

How does PolyPid compare to Neumora Therapeutics?

Summary

How does PolyPid compare to Turn Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PYPD vs. The Competition

PolyPid Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

PolyPid (PYPD) Competitors

PYPD vs. IKT, VNDA, AMRN, NMRA, and TTRX

How does PolyPid compare to Inhibikase Therapeutics?

Which has higher valuation & earnings, IKT or PYPD?

Do institutionals & insiders believe in IKT or PYPD?

Is IKT or PYPD more profitable?

Does the media favor IKT or PYPD?

Which has more risk & volatility, IKT or PYPD?

Do analysts prefer IKT or PYPD?

Summary

How does PolyPid compare to Vanda Pharmaceuticals?

Do analysts rate PYPD or VNDA?

Do institutionals and insiders hold more shares of PYPD or VNDA?

Is PYPD or VNDA more profitable?

Does the media favor PYPD or VNDA?

Which has stronger earnings & valuation, PYPD or VNDA?

Which has more volatility and risk, PYPD or VNDA?

Summary

How does PolyPid compare to Amarin?

Do analysts prefer PYPD or AMRN?

Is PYPD or AMRN more profitable?

Does the media prefer PYPD or AMRN?

Which has preferable valuation and earnings, PYPD or AMRN?

Do institutionals and insiders have more ownership in PYPD or AMRN?

Which has more risk & volatility, PYPD or AMRN?

Summary

How does PolyPid compare to Neumora Therapeutics?

Is PYPD or NMRA more profitable?

Which has more risk & volatility, PYPD or NMRA?

Does the media refer more to PYPD or NMRA?

Do institutionals & insiders hold more shares of PYPD or NMRA?

Which has stronger valuation & earnings, PYPD or NMRA?

Do analysts rate PYPD or NMRA?

Summary

How does PolyPid compare to Turn Therapeutics?

Which has stronger earnings & valuation, PYPD or TTRX?

Is PYPD or TTRX more profitable?

Does the media refer more to PYPD or TTRX?

Do institutionals and insiders have more ownership in PYPD or TTRX?

Do analysts prefer PYPD or TTRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PYPD vs. The Competition

PolyPid Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools